New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives

Szilvia Kanizsai, József Ongrádi, J. Aradi, K. Nagy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thiolated pyrimidine derivatives have been synthetized and their antiretroviral effect against human immunodeficiency virus type 1 (HIV-1IIIB) and HIV-1 chimeric pseudovirions have been quantitatively determined in cell-based viral infectivity assays including syncytium inhibition assay as well as a single-cycle viral infection assay on HeLaCD4-LTR/ß-gal cells. Pseudotype virions prepared bearing HIV-1 envelope preference for CCR5 coreceptor, CXCR4 coreceptor or for both, respectively, with a HIV-1 core containing luciferase reporter gene were able to infect susceptible cells but are replication defective so unable to replicate in the cells . Data indicate that thiolated pyrimidine derivatives inhibited effectively virally induced cell fusion in vitro as well as infectivity of primary HIV-1IIIB strain and HIV-1 pseudovirions using chemokine receptors CCR5 or CXCR4 or both for virus entry a dose dependent manner. Inhibition was selective, depended on the pseudovirus coreceptor preference. Our results suggest that some of these sulfur containing pyrimidines interact with redoxactive -SH groups required for successful HIV entry, including a redox active disulfide in the CD4 molecule as well as -SH groups in HIV viral envelope gp120. This mode of action is unique representing a new class of potential HIV entry inhibitors.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Feb 9 2016

Fingerprint

HIV-1
Binding Sites
HIV
HIV Fusion Inhibitors
Virus Internalization
Pyrimidines
CD4 Antigens
Cell Fusion
Chemokine Receptors
Virus Diseases
Giant Cells
Luciferases
Reporter Genes
Sulfur
Disulfides
Virion
Oxidation-Reduction
pyrimidine

Keywords

  • CD4
  • HIV entry
  • HIV-1 pseudotypes
  • Redox processes
  • Thiolated pyrimidine derivatives

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

New Approach for Inhibition of HIV Entry : Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives. / Kanizsai, Szilvia; Ongrádi, József; Aradi, J.; Nagy, K.

In: Pathology and Oncology Research, 09.02.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{2e931268a22b4a96b257d28a3c7d9d46,
title = "New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives",
abstract = "Thiolated pyrimidine derivatives have been synthetized and their antiretroviral effect against human immunodeficiency virus type 1 (HIV-1IIIB) and HIV-1 chimeric pseudovirions have been quantitatively determined in cell-based viral infectivity assays including syncytium inhibition assay as well as a single-cycle viral infection assay on HeLaCD4-LTR/{\ss}-gal cells. Pseudotype virions prepared bearing HIV-1 envelope preference for CCR5 coreceptor, CXCR4 coreceptor or for both, respectively, with a HIV-1 core containing luciferase reporter gene were able to infect susceptible cells but are replication defective so unable to replicate in the cells . Data indicate that thiolated pyrimidine derivatives inhibited effectively virally induced cell fusion in vitro as well as infectivity of primary HIV-1IIIB strain and HIV-1 pseudovirions using chemokine receptors CCR5 or CXCR4 or both for virus entry a dose dependent manner. Inhibition was selective, depended on the pseudovirus coreceptor preference. Our results suggest that some of these sulfur containing pyrimidines interact with redoxactive -SH groups required for successful HIV entry, including a redox active disulfide in the CD4 molecule as well as -SH groups in HIV viral envelope gp120. This mode of action is unique representing a new class of potential HIV entry inhibitors.",
keywords = "CD4, HIV entry, HIV-1 pseudotypes, Redox processes, Thiolated pyrimidine derivatives",
author = "Szilvia Kanizsai and J{\'o}zsef Ongr{\'a}di and J. Aradi and K. Nagy",
year = "2016",
month = "2",
day = "9",
doi = "10.1007/s12253-016-0044-y",
language = "English",
pages = "1--7",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - New Approach for Inhibition of HIV Entry

T2 - Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives

AU - Kanizsai, Szilvia

AU - Ongrádi, József

AU - Aradi, J.

AU - Nagy, K.

PY - 2016/2/9

Y1 - 2016/2/9

N2 - Thiolated pyrimidine derivatives have been synthetized and their antiretroviral effect against human immunodeficiency virus type 1 (HIV-1IIIB) and HIV-1 chimeric pseudovirions have been quantitatively determined in cell-based viral infectivity assays including syncytium inhibition assay as well as a single-cycle viral infection assay on HeLaCD4-LTR/ß-gal cells. Pseudotype virions prepared bearing HIV-1 envelope preference for CCR5 coreceptor, CXCR4 coreceptor or for both, respectively, with a HIV-1 core containing luciferase reporter gene were able to infect susceptible cells but are replication defective so unable to replicate in the cells . Data indicate that thiolated pyrimidine derivatives inhibited effectively virally induced cell fusion in vitro as well as infectivity of primary HIV-1IIIB strain and HIV-1 pseudovirions using chemokine receptors CCR5 or CXCR4 or both for virus entry a dose dependent manner. Inhibition was selective, depended on the pseudovirus coreceptor preference. Our results suggest that some of these sulfur containing pyrimidines interact with redoxactive -SH groups required for successful HIV entry, including a redox active disulfide in the CD4 molecule as well as -SH groups in HIV viral envelope gp120. This mode of action is unique representing a new class of potential HIV entry inhibitors.

AB - Thiolated pyrimidine derivatives have been synthetized and their antiretroviral effect against human immunodeficiency virus type 1 (HIV-1IIIB) and HIV-1 chimeric pseudovirions have been quantitatively determined in cell-based viral infectivity assays including syncytium inhibition assay as well as a single-cycle viral infection assay on HeLaCD4-LTR/ß-gal cells. Pseudotype virions prepared bearing HIV-1 envelope preference for CCR5 coreceptor, CXCR4 coreceptor or for both, respectively, with a HIV-1 core containing luciferase reporter gene were able to infect susceptible cells but are replication defective so unable to replicate in the cells . Data indicate that thiolated pyrimidine derivatives inhibited effectively virally induced cell fusion in vitro as well as infectivity of primary HIV-1IIIB strain and HIV-1 pseudovirions using chemokine receptors CCR5 or CXCR4 or both for virus entry a dose dependent manner. Inhibition was selective, depended on the pseudovirus coreceptor preference. Our results suggest that some of these sulfur containing pyrimidines interact with redoxactive -SH groups required for successful HIV entry, including a redox active disulfide in the CD4 molecule as well as -SH groups in HIV viral envelope gp120. This mode of action is unique representing a new class of potential HIV entry inhibitors.

KW - CD4

KW - HIV entry

KW - HIV-1 pseudotypes

KW - Redox processes

KW - Thiolated pyrimidine derivatives

UR - http://www.scopus.com/inward/record.url?scp=84957673321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957673321&partnerID=8YFLogxK

U2 - 10.1007/s12253-016-0044-y

DO - 10.1007/s12253-016-0044-y

M3 - Article

C2 - 26860867

AN - SCOPUS:84957673321

SP - 1

EP - 7

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -